USAResearch and clinical trials
Intravenous arginine showed no benefit for sickle cell pain crises in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The STArT study, published in JAMA, examined arginine in sickle cell pain crises. In the USA, 271 patients aged 3 to 21 years were treated at 10 children's hospitals. The time for the crisis to resolve was similar in the arginine and placebo groups. For this reason, the study was stopped early.
What does it mean for patients and families?
In this study, arginine did not shorten pain crises. Treatment of crises should be discussed with the patient's own physician.
Source
Scientific paper: Arginine Therapy for Sickle Cell Disease Acute Pain Episodes. JAMA, 2026. DOI: 10.1001/jama.2026.13310 · PubMed 42616542
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Sickle cell disease
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.